1. ALARA in rhTSH-stimulated post-surgical thyroid remnant ablation: what is the lowest reasonably achievable activity?

   • Daniele Barbaro
   • Frederik A. Verburg
   • Domenico Rubello

   Editorial 20 March 2010 Pages: 1251 - 1254

2. PET and PET/CT in gastrointestinal stromal tumours: the unanswered questions and the potential newer applications

   • Sandip Basu

   Editorial 18 March 2010 Pages: 1255 - 1258

3. Clinical value of FDG PET/CT in the diagnosis of suspected recurrent ovarian cancer: is there an impact of FDG PET/CT on patient management?

   • Ahmet Bilici
   • Bala Basak Oven Ustaalioglu
   • Mahmut Gumus

   Original Article 23 March 2010 Pages: 1259 - 1269

   

4. Clinical and survival impact of FDG PET in patients with suspicion of recurrent cervical carcinoma

   • Amandine Pallardy
   • Caroline Bodet-Milin
   • Caroline Rousseau

   Original Article 20 March 2010 Pages: 1270 - 1278

   

5. Dosimetry for ¹³¹I-MIBG therapies in metastatic neuroblastoma, phaeochromocytoma and paraganglioma

   • Ferdinand Sudbrock
   • Matthias Schmidt
   • Harald Schicha

   Original Article 24 February 2010 Pages: 1279 - 1290

   

6. Imaging of proliferation with ¹⁸F-FLT PET/CT versus ¹⁸F-FDG PET/CT in non-small-cell lung cancer

   • Wenfeng Yang
   • Yongming Zhang
   • Anqin Han

   Original Article 23 March 2010 Pages: 1291 - 1299

   

7. FDG positron emission tomography/computed tomography studies of Wilms’ tumor

   • A. K. M. Moinul Hossain
   • Barry L. Shulkin
   • Jeffrey S. Dome

   Original Article 04 March 2010 Pages: 1300 - 1308

   

8. Utility of positron emission tomography for tumour surveillance in children with neurofibromatosis type 1

   • Mahendranath Moharir
   • Kevin London
   • Kathryn North

   Original Article 24 February 2010 Pages: 1309 - 1317

   

9. ¹⁸F-FDG versus ¹¹C-choline PET/CT for the imaging of advanced head and neck cancer after combined intra-arterial chemotherapy and radiotherapy: the time period during which PET/CT can reliably detect non-recurrence

   • Kimiteru Ito
   • Jyunkichi Yokoyama
   • Hiroshi Matsuda

   Original Article 20 March 2010 Pages: 1318 - 1327

   

10. Optimizing the colloid particle concentration for improved preoperative and intraoperative image-guided detection of sentinel nodes in prostate cancer

    • Lenka Vermeeren
    • Sara H. Muller
    • Renato A. Valdés Olmos

    Original Article 20 March 2010 Pages: 1328 - 1334

    

11. Targeted alpha-radionuclide therapy of functionally critically located gliomas with ²¹³Bi-DOTA-[Thi⁸,Met(O₂)¹¹]-substance P: a pilot trial

    • D. Cordier
    • F. Forrer
    • A. Merlo

    Original Article 16 February 2010 Pages: 1335 - 1344

    

12. ⁶⁸Ga-labelled exendin-3, a new agent for the detection of insulinomas with PET

    • Maarten Brom
    • Wim J. G. Oyen
    • Otto C. Boerman

    Original Article Open access 29 January 2010 Pages: 1345 - 1355

    

13. A HER2-binding Affibody molecule labelled with ⁶⁸Ga for PET imaging: direct in vivo comparison with the ¹¹¹In-labelled analogue

    • Vladimir Tolmachev
    • Irina Velikyan
    • Anna Orlova

    Original Article 04 February 2010 Pages: 1356 - 1367

    

14. PET imaging of HER1-expressing xenografts in mice with ⁸⁶Y-CHX-A″-DTPA-cetuximab

    • Tapan K. Nayak
    • Celeste A. S. Regino
    • Martin W. Brechbiel

    Original Article 13 February 2010 Pages: 1368 - 1376

    

15. Assessment of the Na/I symporter as a reporter gene to visualize oncolytic adenovirus propagation in peritoneal tumours

    • Andrew Merron
    • Patrick Baril
    • Georges Vassaux

    Original Article 06 February 2010 Pages: 1377 - 1385

    

16. A standardised study to compare prostate cancer targeting efficacy of five radiolabelled bombesin analogues

    • Rogier P. J. Schroeder
    • Cristina Müller
    • Marion de Jong

    Original Article Open access 25 February 2010 Pages: 1386 - 1396

    

17. ⁶⁸Ga-labelled recombinant antibody variants for immuno-PET imaging of solid tumours

    • Matthias Eder
    • Stefan Knackmuss
    • Michael Eisenhut

    Original Article 16 February 2010 Pages: 1397 - 1407

    

18. Methodological considerations in quantification of oncological FDG PET studies

    • Dennis Vriens
    • Eric P. Visser
    • Wim J. G. Oyen

    Review Article Open access 20 November 2009 Pages: 1408 - 1425

    

19. PET-guided prostate cancer radiotherapy: technological innovations for dose delivery optimisation

    • Giovanni Lucignani
    • Habib Zaidi

    Focus on 23 April 2010 Pages: 1426 - 1429

20. Comment on: “FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging, version 1.0”

    • Babak Saboury
    • Drew A. Torigian
    • Abass Alavi

    Letter to the Editor 26 May 2010 Pages: 1430 - 1431

21. Reply to: FDG PET and PET/CT: EANM procedure guideline for tumour PET imaging

    • Ronald Boellaard
    • Mike J O’Doherty
    • on behalf of the authors of the guideline “FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging”

    Letter to the Editor Open access 26 May 2010 Pages: 1432 - 1433

22. The diagnostic accuracy of ¹⁸F-FDG PET in cutaneous malignant melanoma

    • Bruno Krug
    • Anne-Sophie Pirson
    • Thierry Vander Borght

    Letter to the Editor 26 May 2010 Pages: 1434 - 1435

23. Reply to: The diagnostic accuracy of ¹⁸F-FDG PET in cutaneous malignant melanoma

    • Roberto C. Delgado-Bolton
    • Felisa Jiménez-Requena
    • José L. Carreras-Delgado

    Letter to the Editor Open access 26 May 2010 Pages: 1436 - 1437

24. An unusual looking pacemaker infection imaged with ¹⁸F-FDG PET/CT

    • Sophie Turpin
    • Raymond Lambert
    • Nancy Poirier

    Image of the Month 07 April 2010 Pages: 1438 - 1438

    

25. ‘Running on empty’

    • Damian Wild
    • Aikaterini Theodoraki
    • Bernard Khoo

    Image of the Month 24 April 2010 Pages: 1439 - 1440

    

26. ¹¹¹In-pentetreotide scintigraphy: procedure guidelines for tumour imaging

    • Emilio Bombardieri
    • Valentina Ambrosini
    • Arturo Chiti

    Guidelines 12 May 2010 Pages: 1441 - 1448